The class
Chromanol derivatives emerge as a novel class of orally active CETP inhibitors suitable for clinical development (Bioorg Med Chem Lett 2011)
Original title: Chromanol derivatives--a novel class of CETP inhibitors
Building on the earlier development candidate BAY 38-1315, optimisation work led to the discovery of chromanol derivatives as a novel chemical class of orally active CETP inhibitors. The lead compound, chromanol derivative 19b, is a highly potent CETP inhibitor with pharmacokinetic properties favourable for clinical studies. Chemical process optimisation also produced a robust, scalable synthesis suitable for kilogram-scale production.
Original abstract
Based on our former development candidate BAY 38-1315, optimization efforts led to the discovery of a novel chemical class of orally active cholesteryl ester transfer protein (CETP) inhibitors. The chromanol derivative 19b is a highly potent CETP inhibitor with favorable pharmacokinetic properties suitable for clinical studies. Chemical process optimization furnished a robust synthesis for a kilogram-scale process.
the classmechanismspharmacology
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 19 August 2026. Methods.